Moderna (MRNA) Share-based Compensation (2018 - 2026)

Moderna (MRNA) has 9 years of Share-based Compensation data on file, last reported at $104.0 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $104.0 million, down 9.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $472.0 million (up 6.55% YoY), and the FY2025 annual result was $483.0 million, up 12.59% from the prior year.
• Share-based Compensation declined to $104.0 million in Q1 2026 per MRNA's latest filing, from $113.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $130.0 million in Q2 2025 and troughed at $44.0 million in Q1 2022.
• A 5-year average of $91.0 million and a median of $101.0 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2026: Share-based Compensation soared 75.0% in 2022, then slipped 9.57% in 2026.
• A 5-year view of Share-based Compensation shows it stood at $62.0 million in 2022, then advanced by 27.42% to $79.0 million in 2023, then soared by 31.65% to $104.0 million in 2024, then rose by 8.65% to $113.0 million in 2025, then slipped by 7.96% to $104.0 million in 2026.
• Business Quant data shows MRNA's Share-based Compensation at $104.0 million in Q1 2026, $113.0 million in Q4 2025, and $125.0 million in Q3 2025.